Profile data is unavailable for this security.
About the company
Crinetics Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead development candidate, PALSONIFY (paltusotine), is the first investigational once-daily, oral, selective somatostatin receptor type 2 (SST2) nonpeptide agonist that is in clinical development for acromegaly and carcinoid syndrome associated with neuroendocrine tumors. Its second product candidate is Atumelnant, which is in clinical development for congenital adrenal hyperplasia (CAH) and patients with either Cushing's disease or Ectopic ACTH Syndrome (EAS). Its drug candidates are orally delivered, small molecule new chemical entities resulting from in-house drug discovery efforts, including other programs addressing a variety of endocrine conditions such as hyperparathyroidism, polycystic kidney disease, Graves' disease, thyroid eye disease, diabetes and obesity.
- Revenue in USD (TTM)1.54m
- Net income in USD-423.10m
- Incorporated2008
- Employees437.00
- LocationCrinetics Pharmaceuticals Inc6055 Lusk Blvd.SAN DIEGO 92121United StatesUSA
- Phone+1 (858) 450-6464
- Fax+1 (302) 636-5454
- Websitehttps://www.crinetics.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Viking Therapeutics Inc | 0.00 | -359.64m | 3.52bn | 53.00 | -- | 5.47 | -- | -- | -3.18 | -3.18 | 0.00 | 5.57 | 0.00 | -- | -- | 0.00 | -44.29 | -31.71 | -47.32 | -33.62 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -227.05 | -- | -- | -- |
| Erasca Inc | 0.00 | -127.69m | 3.85bn | 103.00 | -- | 10.15 | -- | -- | -0.4506 | -0.4506 | 0.00 | 1.23 | 0.00 | -- | -- | 0.00 | -26.90 | -41.53 | -28.68 | -44.78 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -29.28 | -- | -36.84 | -- |
| Grail Inc | 141.83m | -406.24m | 3.86bn | 1.00k | -- | 1.60 | -- | 27.22 | -11.63 | -11.63 | 4.06 | 61.94 | 0.0496 | -- | 9.01 | 141,827.00 | -14.21 | -49.71 | -14.65 | -50.85 | 46.88 | 39.69 | -286.43 | -3,510.18 | -- | -- | 0.00 | -- | 34.90 | -- | -38.30 | -- | 9.34 | -- |
| ACADIA Pharmaceuticals Inc | 1.05bn | 261.17m | 3.88bn | 653.00 | 14.78 | 4.23 | 14.11 | 3.71 | 1.55 | 1.55 | 6.21 | 5.42 | 0.9075 | 1.88 | 9.78 | 1,603,550.00 | 22.64 | -13.15 | 32.50 | -16.74 | 91.92 | 94.49 | 24.94 | -16.00 | 2.94 | -- | 0.00 | -- | 31.85 | 23.08 | 469.50 | -- | -14.26 | -- |
| Arcellx Inc | 35.90m | -217.90m | 4.06bn | 163.00 | -- | 9.20 | -- | 113.08 | -3.92 | -3.92 | 0.6462 | 7.63 | 0.0505 | -- | 9.57 | 220,233.10 | -30.67 | -27.24 | -37.39 | -32.13 | -- | -- | -607.01 | -212.50 | -- | -- | 0.00 | -- | -2.16 | -- | -51.86 | -- | 28.52 | -- |
| Crinetics Pharmaceuticals Inc | 1.54m | -423.10m | 4.14bn | 437.00 | -- | 3.85 | -- | 2,700.25 | -4.53 | -4.53 | 0.0165 | 11.34 | 0.0014 | -- | 0.2622 | 3,512.59 | -39.66 | -36.96 | -42.19 | -39.20 | -- | -- | -27,563.32 | -7,785.98 | -- | -- | 0.00 | -- | -74.11 | -2.73 | -39.10 | -- | 50.86 | -- |
| Terns Pharmaceuticals Inc | 0.00 | -94.44m | 4.20bn | 59.00 | -- | 12.19 | -- | -- | -1.03 | -1.03 | 0.00 | 3.25 | 0.00 | -- | -- | 0.00 | -27.78 | -32.69 | -28.92 | -35.03 | -- | -- | -- | -33,013.70 | -- | -- | 0.00 | -- | -- | -- | 1.50 | -- | -45.82 | -- |
| Gyroscope Therapeutics Holdings Ltd(ADR) | -100.00bn | -100.00bn | 4.23bn | 167.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -70.87 | -- | -58.56 | -- | -- | -- |
| BillionToOne Inc | -100.00bn | -100.00bn | 4.26bn | -- | -- | -- | -- | -- | -- | -- | -- | 4.02 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 5.75 | -- | 0.238 | -- | 112.72 | -- | 49.72 | -- | -- | -- |
| CG Oncology Inc | 2.17m | -151.48m | 4.35bn | 113.00 | -- | 6.13 | -- | 1,998.84 | -2.03 | -2.03 | 0.0292 | 8.78 | 0.0034 | -- | 6.67 | 19,238.94 | -23.63 | -- | -24.51 | -- | 4.09 | -- | -6,967.99 | -- | 22.74 | -- | 0.0043 | -- | 458.33 | -- | -29.85 | -- | -- | -- |
| Amicus Therapeutics, Inc. | 598.70m | -14.06m | 4.49bn | 499.00 | -- | 19.14 | -- | 7.50 | -0.0458 | -0.0458 | 1.94 | 0.7469 | 0.7234 | 0.4175 | 5.65 | 1,199,808.00 | -1.70 | -23.63 | -2.17 | -28.66 | 89.77 | 89.34 | -2.35 | -53.29 | 2.09 | 0.8067 | 0.6298 | -- | 32.29 | 23.72 | 62.99 | -- | -29.23 | -- |
| Scholar Rock Holding Corp | 0.00 | -353.43m | 4.74bn | 196.00 | -- | 18.80 | -- | -- | -3.15 | -3.15 | 0.00 | 2.47 | 0.00 | -- | -- | 0.00 | -119.63 | -45.06 | -144.40 | -51.62 | -- | -- | -- | -1,134.62 | -- | -- | 0.2891 | -- | -- | -- | -48.56 | -- | -49.93 | -- |
| Apogee Therapeutics Inc | 0.00 | -253.67m | 4.76bn | 196.00 | -- | 7.04 | -- | -- | -4.36 | -4.36 | 0.00 | 9.89 | 0.00 | -- | -- | 0.00 | -36.18 | -- | -37.98 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -116.88 | -- | -- | -- |
| Structure Therapeutics Inc (ADR) | 0.00 | -210.69m | 4.94bn | 218.00 | -- | -- | -- | -- | -3.65 | -3.65 | 0.00 | -- | 0.00 | -- | -- | 0.00 | -23.87 | -- | -25.17 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -36.72 | -- | -- | -- |
Data as of Feb 17 2026. Currency figures normalised to Crinetics Pharmaceuticals Inc's reporting currency: US Dollar USD
70.15%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Fidelity Management & Research Co. LLCas of 30 Sep 2025 | 12.54m | 13.31% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 8.35m | 8.87% |
| Farallon Capital Management LLCas of 31 Dec 2025 | 8.02m | 8.52% |
| Wellington Management Co. LLPas of 30 Sep 2025 | 7.93m | 8.42% |
| BlackRock Fund Advisorsas of 31 Dec 2025 | 6.94m | 7.37% |
| Driehaus Capital Management LLCas of 30 Sep 2025 | 6.48m | 6.88% |
| T. Rowe Price Associates, Inc. (IM)as of 30 Sep 2025 | 5.20m | 5.53% |
| EcoR1 Capital, LLCas of 30 Sep 2025 | 4.29m | 4.55% |
| Janus Henderson Investors US LLCas of 30 Sep 2025 | 3.76m | 3.99% |
| Paradigm BioCapital Advisors LPas of 30 Sep 2025 | 2.55m | 2.71% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
